RATIONALE: Lung clearance index (LCI), measured by multiple breath washout (MBW), is a noninvasive measure of ventilation inhomogeneity that holds promise as an objective physiologic endpoint for clinical trials in infants and preschool children with cystic fibrosis (CF). OBJECTIVES: To study the feasibility of using LCI to assess treatment effect outcomes in CF trials of infants and preschoolers. METHODS: The Infant Study of Inhaled Saline trial was a multicenter, randomized, controlled trial of hypertonic (7%) versus isotonic (0.9%) saline inhaled twice daily for 48 weeks in children with CF under 6 years of age. LCI measurements were performed in a single-center pilot substudy at baseline and 48 weeks using a respiratory mass spectrometer and sulfur hexafluoride as the tracer gas. LCI measurements were standardized using published normative data (zLCI) to account for height-related changes in LCI during early childhood. A generalized estimating equation model with an interaction between treatment group and test occasion was used to estimate a treatment effect. MEASUREMENTS AND MAIN RESULTS:A total of 27 participants were randomized; 25 participants, aged (median [range]) 2.6 (0.34-4.95) years, had acceptable baseline and follow-up LCI measures. On average, LCI decreased in the hypertonic saline group (n = 12) by 1.19 z-scores units (95% confidence interval [CI] = -2.46 to 0.06), and remained stable in the isotonic saline group (n = 13) at 0.81 (95% CI = -0.40 to 2.02). A significant treatment effect was observed for zLCI (2.01; 95% CI = 0.26 to 3.76; P = 0.025). CONCLUSIONS: MBW testing is feasible in an interventional study in infants and preschool children with CF. These pilot findings support the development of MBW and LCI as an objective outcome measure in interventional trials in young children with CF, and provide estimates for sample size calculations for future studies.
RCT Entities:
RATIONALE: Lung clearance index (LCI), measured by multiple breath washout (MBW), is a noninvasive measure of ventilation inhomogeneity that holds promise as an objective physiologic endpoint for clinical trials in infants and preschool children with cystic fibrosis (CF). OBJECTIVES: To study the feasibility of using LCI to assess treatment effect outcomes in CF trials of infants and preschoolers. METHODS: The Infant Study of Inhaled Saline trial was a multicenter, randomized, controlled trial of hypertonic (7%) versus isotonic (0.9%) saline inhaled twice daily for 48 weeks in children with CF under 6 years of age. LCI measurements were performed in a single-center pilot substudy at baseline and 48 weeks using a respiratory mass spectrometer and sulfur hexafluoride as the tracer gas. LCI measurements were standardized using published normative data (zLCI) to account for height-related changes in LCI during early childhood. A generalized estimating equation model with an interaction between treatment group and test occasion was used to estimate a treatment effect. MEASUREMENTS AND MAIN RESULTS: A total of 27 participants were randomized; 25 participants, aged (median [range]) 2.6 (0.34-4.95) years, had acceptable baseline and follow-up LCI measures. On average, LCI decreased in the hypertonicsaline group (n = 12) by 1.19 z-scores units (95% confidence interval [CI] = -2.46 to 0.06), and remained stable in the isotonic saline group (n = 13) at 0.81 (95% CI = -0.40 to 2.02). A significant treatment effect was observed for zLCI (2.01; 95% CI = 0.26 to 3.76; P = 0.025). CONCLUSIONS: MBW testing is feasible in an interventional study in infants and preschool children with CF. These pilot findings support the development of MBW and LCI as an objective outcome measure in interventional trials in young children with CF, and provide estimates for sample size calculations for future studies.
Authors: S C Ranganathan; C Dezateux; A Bush; S B Carr; R A Castle; S Madge; J Price; J Stroobant; A Wade; C Wallis; J Stocks Journal: Lancet Date: 2001-12-08 Impact factor: 79.321
Authors: Mark R Elkins; Michael Robinson; Barbara R Rose; Colin Harbour; Carmel P Moriarty; Guy B Marks; Elena G Belousova; Wei Xuan; Peter T P Bye Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Scott H Donaldson; William D Bennett; Kirby L Zeman; Michael R Knowles; Robert Tarran; Richard C Boucher Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: R J Kuczmarski; C L Ogden; L M Grummer-Strawn; K M Flegal; S S Guo; R Wei; Z Mei; L R Curtin; A F Roche; C L Johnson Journal: Adv Data Date: 2000-06-08
Authors: Susanne I Fuchs; Helmut Ellemunter; Johannes Eder; Uwe Mellies; Jörg Grosse-Onnebrink; Burkhard Tümmler; Doris Staab; Andrea Jobst; Matthias Griese; Jan Ripper; Ernst Rietschel; Susanne Zeidler; Frank Ahrens; Monika Gappa Journal: Pediatr Pulmonol Date: 2011-12-13
Authors: Marcus J Couch; Robert Thomen; Nikhil Kanhere; Raymond Hu; Felix Ratjen; Jason Woods; Giles Santyr Journal: J Cyst Fibros Date: 2019-03-25 Impact factor: 5.482
Authors: Felix Ratjen; Michelle Klingel; Philip Black; Michael R Powers; Hartmut Grasemann; Melinda Solomon; Scott D Sagel; Scott H Donaldson; Steven M Rowe; Margaret Rosenfeld Journal: Am J Respir Crit Care Med Date: 2018-08-15 Impact factor: 21.405
Authors: Susan E Birket; Joy M Davis; Courtney M Fernandez; Katherine L Tuggle; Ashley M Oden; Kengyeh K Chu; Guillermo J Tearney; Michelle V Fanucchi; Eric J Sorscher; Steven M Rowe Journal: JCI Insight Date: 2018-01-11
Authors: Sanja Stanojevic; Stephanie D Davis; George Retsch-Bogart; Hailey Webster; Miriam Davis; Robin C Johnson; Renee Jensen; Maria Ester Pizarro; Mica Kane; Charles C Clem; Leah Schornick; Padmaja Subbarao; Felix A Ratjen Journal: Am J Respir Crit Care Med Date: 2017-05-01 Impact factor: 21.405
Authors: Felix Ratjen; Scott C Bell; Steven M Rowe; Christopher H Goss; Alexandra L Quittner; Andrew Bush Journal: Nat Rev Dis Primers Date: 2015-05-14 Impact factor: 52.329